CTLA4 and glioblastoma: Importantly, a phase 2a trial involving an implantable ultrasound device (Sonocloud‐9) with concomitant balstilimab (anti‐CTLA‐4 antibody), botensilimab (anti‐PD‐1 antibody), and liposomal doxorubicin is actively ongoing for newly diagnosed GBM patients (NCT05864534).